GB9017482D0 — Manufacturing process
Assigned to Imperial Chemical Industries Ltd · Expires 1990-09-26 · 36y expired
What this patent protects
The invention provides a novel process for the manufacture of biphenylcarbonitriles of the formula III as defined hereinafter which are useful for the production of certain known imidazole derivatives and certain novel quinoline derivatives which have angiotensin II inhibitory ac…
USPTO Abstract
The invention provides a novel process for the manufacture of biphenylcarbonitriles of the formula III as defined hereinafter which are useful for the production of certain known imidazole derivatives and certain novel quinoline derivatives which have angiotensin II inhibitory activity. The process involves a palladium- or nickel-catalysed reaction of a boron compound of the formula II with a nitrile of the formula III in which the variables L<1>, L<2>, Q<1> and Q<2> have the various meanings defined hereinafter. Certain of the biphenylcarbonitriles are novel and are provided as a further feature of the invention. The invention also provides a novel process for the production of the known and novel angiotensin II inhibitors of formula VI and VII as defined hereinafter.
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.